• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过肽掺入对48型腺病毒纤维钮结构域进行重靶向。

Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

作者信息

Coughlan Lynda, Uusi-Kerttula Hanni, Ma Jiangtao, Degg Bethany P, Parker Alan L, Baker Andrew H

机构信息

1 British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA, United Kingdom .

出版信息

Hum Gene Ther. 2014 Apr;25(4):385-94. doi: 10.1089/hum.2014.016. Epub 2014 Apr 11.

DOI:10.1089/hum.2014.016
PMID:24617540
Abstract

Adenovirus type 5 (Ad5) is a commonly used vector for gene therapy, but its efficacy is limited by high seroprevalence and off-target hepatic and splenic sequestration. In order to circumvent these limitations, the use of vectors derived from rare species adenoviruses is appealing. The opportunity to retarget rare species vectors to defined cell types through the incorporation of peptide ligands would be advantageous, particularly in targeting tumors and disseminated metastases. We used predictive structural modeling to assess the CD, DG, HI, and IJ loops of the Ad48 fiber knob and identify optimal incorporation locales for the 20-mer peptide, A20FMDV2 (A20). A20FMDV2 targets ανβ6 integrin, which is overexpressed in human carcinomas. Recombinant Ad48 fiber knob proteins Knob48, Knob48-CD-A20, Knob48-DG-A20, Knob48-HI-A20, and Knob48-IJ-A20 were engineered and purified after expression in Escherichia coli. We confirmed that Knob48, Knob48-CD-A20, and Knob48-IJ-A20 formed stable homotrimers. However, Knob48-DG-A20 and Knob-HI-A20 failed to form a trimer. All A20-modified knob proteins blocked the transduction of Ad5-EGFPA20 via ανβ6, demonstrating that the inserted A20 peptide was functional. In conclusion, we show that the CD and IJ loops of Ad48 represent suitable sites for targeting peptide incorporation. Interestingly, in vitro gene transfer mediated by the non-factor-X-binding Ad48 vector was not sensitive to immunoglobulins and complement when incubated in the presence of mouse serum, unlike Ad5. These data support the future generation of the corresponding Ad48 viral vectors, Ad48-CD-A20 and Ad48-IJ-A20, which may offer favorable characteristics for targeted delivery in vivo.

摘要

5型腺病毒(Ad5)是基因治疗中常用的载体,但其疗效受到高血清阳性率以及肝脾非靶向性滞留的限制。为了克服这些限制,使用源自稀有物种腺病毒的载体很有吸引力。通过掺入肽配体将稀有物种载体重新靶向特定细胞类型的机会将是有利的,特别是在靶向肿瘤和播散性转移灶方面。我们使用预测性结构建模来评估Ad48纤维钮的CD、DG、HI和IJ环,并确定20聚体肽A20FMDV2(A20)的最佳掺入位点。A20FMDV2靶向αvβ6整合素,其在人类癌症中过表达。重组Ad48纤维钮蛋白Knob48、Knob48-CD-A20、Knob48-DG-A20、Knob48-HI-A20和Knob48-IJ-A20在大肠杆菌中表达后进行工程改造和纯化。我们证实Knob48、Knob48-CD-A20和Knob48-IJ-A20形成了稳定的同三聚体。然而,Knob48-DG-A20和Knob-HI-A20未能形成三聚体。所有A20修饰的钮蛋白均通过αvβ6阻断了Ad5-EGFPA20的转导,表明插入的A20肽具有功能。总之,我们表明Ad48的CD和IJ环是靶向肽掺入的合适位点。有趣的是,与Ad5不同,在小鼠血清存在下孵育时,由非因子X结合的Ad48载体介导的体外基因转移对免疫球蛋白和补体不敏感。这些数据支持未来生成相应的Ad48病毒载体Ad48-CD-A20和Ad48-IJ-A20,它们可能在体内靶向递送方面具有良好特性。

相似文献

1
Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.通过肽掺入对48型腺病毒纤维钮结构域进行重靶向。
Hum Gene Ther. 2014 Apr;25(4):385-94. doi: 10.1089/hum.2014.016. Epub 2014 Apr 11.
2
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.用于卵巢癌治疗的假型αvβ6整合素靶向腺病毒载体
Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545.
3
Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells.携带在人气管腺细胞上筛选出的新型内吞肽配体的纤维修饰5型腺病毒载体的基因转导和细胞进入途径。
J Virol. 2004 Jul;78(13):7227-47. doi: 10.1128/JVI.78.13.7227-7247.2004.
4
Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.通过将肽配体插入腺病毒血清型41短纤维钮结构域的不同位置来修饰腺病毒载体的嗜性。
J Virol. 2007 Mar;81(6):2688-99. doi: 10.1128/JVI.02722-06. Epub 2006 Dec 27.
5
Analysis of the interaction between RGD-expressing adenovirus type 5 fiber knob domains and alphavbeta3 integrin reveals distinct binding profiles and intracellular trafficking.
J Gen Virol. 2006 Sep;87(Pt 9):2497-2505. doi: 10.1099/vir.0.81620-0.
6
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob.一种在纤维钮的HI环中含有异源肽表位的腺病毒载体的特性分析。
J Virol. 1998 Mar;72(3):1844-52. doi: 10.1128/JVI.72.3.1844-1852.1998.
7
Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.溶瘤腺病毒 5 载体在癌症治疗中的趋向性和转导作用:重点关注纤维嵌合体和嵌合性、六邻体和 pIX。
Virus Res. 2018 Sep 15;257:40-51. doi: 10.1016/j.virusres.2018.08.012. Epub 2018 Aug 17.
8
Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob.在纤维钮的HI环和C末端均含有异源肽的纤维修饰腺病毒载体的构建
J Gene Med. 2003 Apr;5(4):267-76. doi: 10.1002/jgm.348.
9
Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob.通过在腺病毒血清型 35 纤维顶端的两个不同区域掺入 RGD 肽,增强纤维替代型腺病毒载体的转导效率。
Virus Res. 2011 Jan;155(1):48-54. doi: 10.1016/j.virusres.2010.08.021. Epub 2010 Aug 27.
10
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.将靶向表皮生长因子受体(EGFR)和纤维母细胞生长因子受体1(FGFR1)的肽段整合到腺病毒纤维钮结构域并将其作为靶向癌症疗法进行评估。
Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015.

引用本文的文献

1
Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.腺病毒载体系统:构建、治疗应用和宿主反应的全面概述。
J Microbiol. 2024 Jul;62(7):491-509. doi: 10.1007/s12275-024-00159-4. Epub 2024 Jul 22.
2
The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.免疫系统——腺病毒疗法的双刃剑。
Viruses. 2024 Jun 17;16(6):973. doi: 10.3390/v16060973.
3
Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?工程化癌症选择性病毒疗法:拼图的各个部分是否正在组合在一起?
Hum Gene Ther. 2022 Nov;33(21-22):1109-1120. doi: 10.1089/hum.2022.178. Epub 2022 Nov 4.
4
Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.腺病毒载体疫苗——新兴病毒病原体大流行防范的平台。
Mol Ther. 2022 May 4;30(5):1822-1849. doi: 10.1016/j.ymthe.2022.01.034. Epub 2022 Jan 31.
5
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.击中目标却未抓住重点:基于腺病毒的精准病毒疗法的最新进展
Cancers (Basel). 2020 Nov 11;12(11):3327. doi: 10.3390/cancers12113327.
6
Retargeting adenoviruses for therapeutic applications and vaccines.靶向腺病毒用于治疗应用和疫苗。
FEBS Lett. 2020 Jun;594(12):1918-1946. doi: 10.1002/1873-3468.13731. Epub 2020 Feb 3.
7
Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.腺病毒纤维扣超变环内的多样性影响主要受体相互作用。
Nat Commun. 2019 Feb 14;10(1):741. doi: 10.1038/s41467-019-08599-y.
8
Designer Oncolytic Adenovirus: Coming of Age.设计型溶瘤腺病毒:走向成熟
Cancers (Basel). 2018 Jun 14;10(6):201. doi: 10.3390/cancers10060201.
9
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.用于卵巢癌治疗的假型αvβ6整合素靶向腺病毒载体
Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545.